Ellis Andrea 4

What Happened

• Andrea Ellis, a director of BridgeBio Pharma (BBIO), received a grant of restricted stock units (RSUs) reported on Form 4. The filing shows two award entries dated June 22, 2026: 3,990 RSUs (acquired) and 5,277 RSUs (derivative), for a total of 9,267 RSUs. Each RSU represents a contingent right to one share; the filing reports $0 purchase price because these are restricted awards, not open-market purchases or sales.

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (timely within the usual two-business-day window).
• Entries: 3,990 RSUs (A — award/grant) and 5,277 RSUs (A — award/grant, derivative), total 9,267 RSUs.
• Price/value reported: $0 (typical for equity awards at grant on Form 4).
• Vesting: The RSUs vest in full on June 22, 2027, subject to Ellis’s continued service on the board (Footnote F1). Footnote F2 confirms each RSU equals a contingent right to one share; footnote F3 reiterates the full vesting date.
• Shares owned after transaction: Not specified in the filed Form 4.
• Transaction code: A = Award/Grant. No 10b5-1 plan, sale, or tax-withholding event was reported.

Context

• These RSUs are compensation awards that do not result in immediate shares or cash; they convert to shares only if vesting conditions are met (here, continued board service through June 22, 2027). Such grants are common for directors and are routine corporate compensation rather than an open-market purchase or sale.